Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.95 | N/A | +0.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.95 | N/A | +0.84% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions and their impact on performance. They are prioritizing cost controls to navigate these challenges.
Management highlighted ongoing challenges in the market.
They emphasized a focus on cost management and operational efficiency.
Natera's earnings report shows a larger-than-expected loss per share, which contributed to a 5.27% decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are facing significant challenges in the current market environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CONSTELLATION ENERGY
Nov 6, 2023